X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (24711) 24711
Newsletter (209) 209
Magazine Article (125) 125
Newspaper Article (57) 57
Book Chapter (51) 51
Book Review (11) 11
Publication (10) 10
Dissertation (8) 8
Transcript (5) 5
Conference Proceeding (4) 4
Reference (3) 3
Archival Material (1) 1
Book / eBook (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (18729) 18729
male (13769) 13769
female (10897) 10897
hypertension - drug therapy (10682) 10682
antihypertensive agents - therapeutic use (10557) 10557
antihypertensive agents - administration & dosage (10356) 10356
middle aged (8437) 8437
hypertension (8404) 8404
blood pressure - drug effects (7052) 7052
aged (6631) 6631
adult (6131) 6131
animals (5872) 5872
antihypertensive agents - pharmacology (5299) 5299
pharmacology & pharmacy (4373) 4373
rats (3903) 3903
hypertension - physiopathology (3870) 3870
blood pressure (3862) 3862
treatment outcome (3850) 3850
antihypertensive agents - adverse effects (3722) 3722
drug therapy, combination (3195) 3195
peripheral vascular disease (3116) 3116
blood-pressure (2720) 2720
risk factors (2646) 2646
antihypertensive drugs (2498) 2498
drug therapy (2307) 2307
dose-response relationship, drug (2214) 2214
time factors (2196) 2196
cardiac & cardiovascular systems (2011) 2011
hypertension - complications (1988) 1988
double-blind method (1899) 1899
aged, 80 and over (1836) 1836
medicine, general & internal (1761) 1761
heart rate - drug effects (1717) 1717
prospective studies (1595) 1595
research (1574) 1574
dosage and administration (1554) 1554
medicine & public health (1540) 1540
care and treatment (1537) 1537
ophthalmology (1489) 1489
administration, oral (1417) 1417
therapy (1372) 1372
angiotensin-converting enzyme inhibitors - therapeutic use (1363) 1363
mortality (1320) 1320
follow-up studies (1278) 1278
rats, inbred shr (1241) 1241
antihypertensive agents - pharmacokinetics (1202) 1202
hypertension - diagnosis (1197) 1197
health aspects (1190) 1190
intraocular pressure - drug effects (1185) 1185
antihypertensive agents (1162) 1162
analysis (1158) 1158
drug combinations (1150) 1150
adolescent (1140) 1140
internal medicine (1124) 1124
drug administration schedule (1116) 1116
management (1112) 1112
risk (1100) 1100
retrospective studies (1072) 1072
glaucoma (1069) 1069
prevention (1063) 1063
hypertension, pulmonary - drug therapy (1048) 1048
angiotensin (1042) 1042
angiotensin-converting enzyme inhibitors - administration & dosage (1042) 1042
rats, sprague-dawley (987) 987
blood pressure - physiology (983) 983
calcium channel blockers - therapeutic use (956) 956
clinical trials as topic (954) 954
drugs (953) 953
prevalence (951) 951
hemodynamics - drug effects (948) 948
diuretics (947) 947
disease (936) 936
double-blind (897) 897
rats, wistar (881) 881
hypertension - epidemiology (871) 871
losartan (867) 867
randomized controlled trials as topic (864) 864
antihypertensives (853) 853
abridged index medicus (834) 834
efficacy (834) 834
diabetes (822) 822
tetrazoles - administration & dosage (815) 815
patient compliance (813) 813
disease models, animal (804) 804
cardiology (801) 801
calcium channel blockers - administration & dosage (782) 782
adrenergic beta-antagonists - therapeutic use (776) 776
angiotensin receptor antagonists (766) 766
renin-angiotensin system - drug effects (752) 752
amlodipine (751) 751
pharmacokinetics (740) 740
tetrazoles - therapeutic use (735) 735
hypertension - metabolism (732) 732
diuretics - therapeutic use (727) 727
physiology (726) 726
pregnancy (720) 720
young adult (719) 719
hypertension - etiology (704) 704
hydrochlorothiazide - administration & dosage (700) 700
pulmonary hypertension (695) 695
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (23065) 23065
German (681) 681
Russian (537) 537
Japanese (498) 498
French (313) 313
Spanish (186) 186
Chinese (105) 105
Italian (93) 93
Polish (83) 83
Portuguese (79) 79
Swedish (63) 63
Danish (58) 58
Norwegian (58) 58
Hungarian (52) 52
Czech (30) 30
Romanian (30) 30
Ukrainian (23) 23
Dutch (16) 16
Turkish (16) 16
Hebrew (14) 14
Finnish (12) 12
Slovak (12) 12
Croatian (9) 9
Lithuanian (8) 8
Bulgarian (7) 7
Serbian (7) 7
Korean (2) 2
Arabic (1) 1
Bosnian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cochrane library, ISSN 1465-1858, 2017, Volume 2017, Issue 3, p. CD009868
Background Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and disability worldwide, yet ASCVD risk factor control and secondary... 
Blood Pressure | Drugs | A.1 Drugs | Anticholesteremic Agents | Aspirin | Cardiovascular Diseases | Heart disease prevention | Costs | A.1.3 Other | Placebo Effect | A. Cardiovascular Disease: Primary Prevention | Insurance medicine | Cause of Death | Cholesterol | Randomized Controlled Trials as Topic | Prevention | Platelet Aggregation Inhibitors | Antihypertensive Agents | Heart & circulation | Medicine General & Introductory Medical Sciences | Drug Combinations | POLYPILL-BASED STRATEGY | Humans | Antihypertensive Agents [administration & dosage] | Anticholesteremic Agents [administration & dosage] | Cardiovascular Diseases [mortality; prevention & control] | RANDOMIZED CONTROLLED-TRIAL | PROACTIVE MULTIFACTORIAL INTERVENTION | Aspirin [administration & dosage] | USUAL CARE | MEDICINE, GENERAL & INTERNAL | Platelet Aggregation Inhibitors [administration & dosage] | HIGH-RISK | DOUBLE-BLIND | SINGLE-PILL COMBINATION | BLOOD-PRESSURE CONTROL | PLACEBO-CONTROLLED TRIAL | CORONARY-HEART-DISEASE | Cardiovascular Diseases - prevention & control | Cholesterol - blood | Middle Aged | Antihypertensive Agents - administration & dosage | Male | Anticholesteremic Agents - adverse effects | Antihypertensive Agents - adverse effects | Aspirin - administration & dosage | Aspirin - adverse effects | Anticholesteremic Agents - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Platelet Aggregation Inhibitors - adverse effects
Journal Article
Journal Article
The American journal of medicine, ISSN 0002-9343, 2012, Volume 125, Issue 9, pp. 882 - 887.e1
Abstract Objective Combination therapy, specifically with aspirin, cholesterol and blood pressure-lowering drugs, substantially reduces the risk of coronary... 
Internal Medicine | Adherence | Prevention | Cardiovascular disease | PERSISTENCE | ACUTE CORONARY SYNDROMES | CONVERTING ENZYME-INHIBITORS | SECONDARY PREVENTION | MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | STATIN THERAPY | ACUTE MYOCARDIAL-INFARCTION | BETA-BLOCKERS | MEDICATION ADHERENCE | ARTERY-DISEASE | Drug Costs | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Medication Adherence - statistics & numerical data | Cardiovascular Agents - administration & dosage | Age Factors | Drug Administration Schedule | Cardiovascular Diseases - prevention & control | Humans | Antihypertensive Agents - administration & dosage | Secondary Prevention - methods | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Aspirin - administration & dosage | Drug Prescriptions - statistics & numerical data | Self Administration | Time Factors | Anticholesteremic Agents - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | Calcium Channel Blockers - administration & dosage | Primary Prevention - methods | Sodium Chloride Symporter Inhibitors - administration & dosage | Myocardial Infarction - prevention & control | Adrenergic beta-Antagonists - administration & dosage | Angiotensin Receptor Antagonists - administration & dosage | Research | Patient compliance | Coronary heart disease | Drugs | Myocardial infarction | Aspirin | Side effects | Enzyme inhibitors | Risk reduction | Age | Statins
Journal Article
Archives of Dermatological Research, ISSN 0340-3696, 1/2009, Volume 301, Issue 1, pp. 99 - 105
Drug-induced lupus erythematosus (DILE) is defined as a lupus-like syndrome temporally related to continuous drug exposure which resolves after discontinuation... 
Drug-induced lupus erythematosus | Antinuclear antibodies (ANA) | Medicine & Public Health | Dermatology | Anti-TNFα-induced lupus | Anti-histone antibodies | Subacute cutaneous drug-induced lupus (SCLE) | Drug reactions | RHEUMATOID-ARTHRITIS | AUTOANTIBODIES | ANTINUCLEAR | NECROSIS-FACTOR-ALPHA | INDUCTION | DERMATOLOGY | Anti-TNF alpha-induced lupus | THERAPY | INFLIXIMAB | ASSOCIATION | EPIDEMIOLOGY | PSORIASIS | Antifungal Agents - adverse effects | Antitubercular Agents - adverse effects | Naphthalenes - adverse effects | Antibodies - metabolism | Calcium Channel Blockers - adverse effects | Serositis | Exanthema | Humans | Isoniazid - adverse effects | Interferons - adverse effects | Antihypertensive Agents - administration & dosage | Sodium Chloride Symporter Inhibitors - adverse effects | Arthritis | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Lupus Erythematosus, Systemic - immunology | Sodium Chloride Symporter Inhibitors - administration & dosage | Tumor Necrosis Factor-alpha - immunology | Antibodies - immunology | Lupus Erythematosus, Cutaneous - chemically induced | Procainamide - administration & dosage | Lupus Erythematosus, Cutaneous - immunology | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Anti-Arrhythmia Agents - administration & dosage | Procainamide - adverse effects | Antihypertensive Agents - adverse effects | Hydralazine - adverse effects | Isoniazid - administration & dosage | Lupus Erythematosus, Systemic - diagnosis | Interferons - administration & dosage | Hydralazine - administration & dosage | Animals | Anti-Arrhythmia Agents - adverse effects | Naphthalenes - administration & dosage | Calcium Channel Blockers - administration & dosage | Antitubercular Agents - administration & dosage | Lupus Erythematosus, Systemic - chemically induced | Antifungal Agents - administration & dosage | Lupus Erythematosus, Cutaneous - diagnosis | Lupus | Antigen-antibody reactions | Enzymes | Antigens | Biological products | Antibodies | Viral antibodies | Enzyme inhibitors | Systemic lupus erythematosus | Fluocinolone acetonide | Calcium channel blockers | Diuretics | Kidney diseases | Hydralazine | Index Medicus
Journal Article
Journal Article
Diabetes care, ISSN 1935-5548, 2015, Volume 38, Issue 3, pp. 420 - 428
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2005, Volume 366, Issue 9489, pp. 895 - 906
.... For a given reduction in blood pressure, some suggested that newer agents would confer advantages over diuretics and β blockers... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | MANAGEMENT | MORBIDITY | DISEASE | GUIDELINES | DOUBLE-BLIND | CALCIUM-ANTAGONISTS | HYPERTENSION | INTERVENTION | Calcium Channel Blockers - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Bendroflumethiazide - administration & dosage | Hypertension - drug therapy | Male | Perindopril - administration & dosage | Sodium Chloride Symporter Inhibitors - administration & dosage | Diuretics | Adrenergic beta-Antagonists - adverse effects | Adult | Female | Blood Pressure - drug effects | Atenolol - administration & dosage | Drug Therapy, Combination | Amlodipine - administration & dosage | Adrenergic beta-Antagonists - administration & dosage | Risk Factors | Amlodipine - adverse effects | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Antihypertensive Agents - adverse effects | Coronary Disease - prevention & control | Calcium Channel Blockers - administration & dosage | Atenolol - adverse effects | Hypertension - complications | Aged | Hypertension | Antihypertensive drugs | Evaluation | Dosage and administration | Drug therapy | Prevention | Drug therapy, Combination | Health aspects | Coronary heart disease | Risk factors | Studies | Drugs | Cardiovascular disease | Medical treatment | Myocardial infarction | Heart attacks | Antihypertensives | Clinical trials | Family medical history | Evidence-based medicine | Blood | Randomization | Motivation | Blood pressure | Heart diseases | Antihypertensive agents | Cerebral infarction | Stroke | Fasting | Mortality | Diabetes mellitus | Health risks | Triglycerides | Metabolism | Risk analysis | Atenolol | Patients | Coronary artery disease | Cholesterol | Heart rate | Infarction | Diabetes | Cardiovascular diseases | Health risk assessment | Potassium | Amlodipine/administration & dosage/adverse effects | Bendroflumethiazide/administration & dosage | Cardiovascular Diseases/prevention & control | Perindopril/administration & dosage | MEDICIN OCH HÄLSOVETENSKAP | Atenolol/administration & dosage/adverse effects | Combination | Antihypertensive Agents/administration & dosage/adverse effects | Angiotensin-Converting Enzyme Inhibitors/administration & dosage | MEDICAL AND HEALTH SCIENCES | Coronary Disease/prevention & control | Drug Therapy | Adrenergic beta-Antagonists/administration & dosage/adverse effects | Blood Pressure/drug effects | Hypertension/complications/drug therapy | Calcium Channel Blockers/administration & dosage/adverse effects | Sodium Chloride Symporter Inhibitors/administration & dosage
Journal Article